AIM ImmunoTech hopes to take the battle against COVID-19 to the front lines of China

AIM ImmunoTech (NYSE:AIM) CEO Thomas Equels joined Proactive New York's Christine Corrado on Skype with news the immuno-pharma company announced they have joined ChinaGoAbroad to bring their experimental drug Ampligen to China.

Equels telling Proactive how this drug will try to be a potential first line of defence against the dealy COVID-19 Virus.

Aim ImmunoTech,Thomas Equels,COVID-19,flu,china,